These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 24061041)

  • 61. Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study.
    Colomba E; Le Teuff G; Eisen T; Stewart GD; Fife K; Larkin J; Biondo A; Pickering L; Srinivasan A; Boyle H; Derosa L; Sternberg CN; Recine F; Ralph C; Saldana C; Barthélémy P; Bernhard JC; Gurney H; Verhoest G; Vauleon E; Bigot P; Berger J; Pfister C; Gravis G; Rodier JM; Culine S; Caty A; Rolland F; Priou F; Escudier B; Albiges L
    Eur J Cancer; 2017 Jul; 80():55-62. PubMed ID: 28549248
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Emerging drugs for renal cell carcinoma.
    Varella L; Rini BI
    Expert Opin Emerg Drugs; 2010 Sep; 15(3):343-53. PubMed ID: 20443750
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Emerging drugs for renal cell carcinoma.
    Shaheen PE; Bukowski RM
    Expert Opin Emerg Drugs; 2005 Nov; 10(4):773-95. PubMed ID: 16262562
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pazopanib for the treatment of renal cancer.
    Al-Marrawi MY; Rini B
    Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
    [TBL] [Abstract][Full Text] [Related]  

  • 65. One decade of improving palliative care of metastatic renal cell carcinoma by antiangiogenic therapies: time to move toward RCC cure.
    Kroeger N; Zimmermann U; Burchardt M
    Int J Cancer; 2015 Apr; 136(7):1483-4. PubMed ID: 25230294
    [No Abstract]   [Full Text] [Related]  

  • 66. Silencing Livin induces apoptotic and autophagic cell death, increasing chemotherapeutic sensitivity to cisplatin of renal carcinoma cells.
    Wang Z; Liu S; Ding K; Ding S; Li C; Lu J; Gao D; Zhang T; Bi D
    Tumour Biol; 2016 Nov; 37(11):15133-15143. PubMed ID: 27677286
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cytoreductive nephrectomy for metastatic renal cell carcinoma.
    McKiernan J; Wood CG
    J Urol; 2013 Aug; 190(2):386-8. PubMed ID: 23702308
    [No Abstract]   [Full Text] [Related]  

  • 68. Evolving landscape of the treatment of metastatic clear cell renal cell carcinoma.
    Ghatalia P; Zibelman MR; Geynisman DM; Plimack ER
    Clin Adv Hematol Oncol; 2018 Oct; 16(10):677-686. PubMed ID: 30543598
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma.
    Polena H; Creuzet J; Dufies M; Sidibé A; Khalil-Mgharbel A; Salomon A; Deroux A; Quesada JL; Roelants C; Filhol O; Cochet C; Blanc E; Ferlay-Segura C; Borchiellini D; Ferrero JM; Escudier B; Négrier S; Pages G; Vilgrain I
    Br J Cancer; 2018 May; 118(9):1179-1188. PubMed ID: 29563634
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pazopanib for the treatment of metastatic renal cell carcinoma.
    Pick AM; Nystrom KK
    Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Therapy management with sunitinib in patients with metastatic renal cell carcinoma: key concepts and the impact of clinical biomarkers.
    Castellano D; Ravaud A; Schmidinger M; De Velasco G; Vazquez F
    Cancer Treat Rev; 2013 May; 39(3):230-40. PubMed ID: 22647546
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Sunitinib for metastatic renal cell carcinoma.
    Mukherji D; Larkin J; Pickering L
    Future Oncol; 2010 Sep; 6(9):1377-85. PubMed ID: 20919823
    [TBL] [Abstract][Full Text] [Related]  

  • 73. What is standard initial systemic therapy in metastatic renal cell carcinoma?
    Rini BI; McDermott D; Atkins M
    Clin Genitourin Cancer; 2007 Mar; 5(4):256-63. PubMed ID: 17553205
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Better effect of sorafenib on the rhabdoid component of a clear cell renal cell carcinoma owing to its higher level of vascular endothelial growth factor-A production.
    Kats-Ugurlu G; Maass C; van Herpen C; de Waal R; Oosterwijk E; Mulders P; Hulsbergen-van de Kaa C; Leenders W
    Histopathology; 2011 Sep; 59(3):562-4. PubMed ID: 22034894
    [No Abstract]   [Full Text] [Related]  

  • 75. Inhibition of BRD4 Suppresses Cell Proliferation and Induces Apoptosis in Renal Cell Carcinoma.
    Wu X; Liu D; Gao X; Xie F; Tao D; Xiao X; Wang L; Jiang G; Zeng F
    Cell Physiol Biochem; 2017; 41(5):1947-1956. PubMed ID: 28391274
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Sequential use of targeted agents in the treatment of renal cell carcinoma.
    Hutson TE; Bukowski RM; Cowey CL; Figlin R; Escudier B; Sternberg CN
    Crit Rev Oncol Hematol; 2011 Jan; 77(1):48-62. PubMed ID: 20705477
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma.
    Ismail S; Meskawi M; Hansen J; Bianchi M; Tian Z; Latour M; Graefen M; Montorsi F; Trinh QD; Perrotte P; Karakiewicz PI; Sun M
    Crit Rev Oncol Hematol; 2014 Apr; 90(1):49-57. PubMed ID: 24411587
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Sorafenib [corrected] in kidney cancer.
    Escudier B
    Ann Oncol; 2007 Jul; 18 Suppl 9():ix90-3. PubMed ID: 17631603
    [No Abstract]   [Full Text] [Related]  

  • 79. Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives.
    Ortolani S; Ciccarese C; Cingarlini S; Tortora G; Massari F
    Future Oncol; 2015; 11(12):1809-28. PubMed ID: 26075448
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Is IL-2 still indicated for melanoma and RCC? What a question to ask!
    Hamid O
    Oncology (Williston Park); 2013 Jul; 27(7):695, 701. PubMed ID: 23977765
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.